Loading...
NPI 1801492558 · Houston, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Texas Diagnostic Laboratories LLC is a clinical medical laboratory provider located in Houston, Texas. This profile covers 80 Medicare and 80 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Texas Diagnostic Laboratories LLC |
| Address | 12000 Westheimer Rd Ste 309 |
| City | Houston |
| State | TX |
| ZIP | 77077 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 8, 2020 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $5.6M |
| Medicaid | $919.6K |
TEXAS DIAGNOSTIC LABORATORIES LLC is coded as a Clinical Medical Laboratory and its Medicare and Medicaid billing mix shows a strong focus on molecular infectious-disease testing and high-throughput COVID services; Medicare top codes include 87798, 87481 and 87483 (all amplified probe/multiplex nucleic acid tests) while Medicaid top activity is dominated by U0003, U0005 and G2023 (SARS-CoV-2 detection and specimen collection). This pattern indicates the operation is oriented toward diagnostic molecular assays and pandemic-era testing workflows rather than routine anatomic pathology or outpatient clinical procedures.
Medicare revenue is highly concentrated: the top three Medicare codes account for 71.5% of the provider’s Medicare revenue, with 87798 alone generating $2.4M (44.7% of Medicare revenue), 87481 contributing $905.8K (16.6%), and 87483 adding $560.6K (10.3%) against a total Medicare revenue of $5.6M. This concentration implies that a relatively small set of high-volume molecular assays drive the majority of Medicare receipts.
Medicaid revenue is even more COVID-centric and concentrated: the top three Medicaid codes account for 85.9% of Medicaid revenue, led by U0003 at $494.7K (54.4%), followed by U0005 at $158.8K (17.5%) and G2023 at $128K (14.1%) out of total Medicaid revenue of $919.6K. Medicaid billing therefore appears dominated by SARS-CoV-2 diagnostic and specimen-collection services rather than a broad panel of routine lab tests.
On competitive standing the provider is a high-volume national player for several Medicare molecular codes: 87481 ranks #16 of 1117 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code), 87483 ranks #1 of 7 providers nationally (100th percentile; notably above typical national volume for this code), and 87798 ranks #27 of 1319 (98th percentile; notably above typical national volume). These ranks indicate the lab captures unusually large national volume for specific amplified-probe tests rather than being a modest or average participant for those services.
Within the state Medicaid market the lab is a major regional COVID tester: U0003 ranks #26 of 337 providers in-state (93rd percentile), U0005 ranks #28 of 257 (89th percentile), and G2023 ranks #15 of 335 (96th percentile). Those state-level percentiles position the provider as a significant in-state source of COVID PCR testing and specimen collection, consistent with the large Medicaid share attributed to those three codes.
Beyond molecular PCR panels, the provider reports extreme or notable national ranks on several immunoassays and serologies on Medicare claims: 86738 (mycoplasma antibody immunoassay) shows $92.4K revenue (1.7% of Medicare) and ranks #1 of 153 providers nationally (100th percentile; extreme outlier), while 86780 (syphilis serology) shows $46.3K (0.8% of Medicare) and ranks #2 of 225 (100th percentile; extreme outlier). These findings suggest meaningful supplementary volumes in serologic testing that augment the laboratory’s primarily molecular testing business.
The provider’s NPI was enumerated on 2020-12-08 (~6 years ago), indicating a relatively recent market entry that has rapidly scaled molecular and COVID testing volumes. Given the timeline and the concentration in high-throughput codes (including several national high-percentile ranks), operational capacity for large-volume nucleic-acid–based testing and specimen processing is likely a core capability of the business.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
80 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 71,900 | $30 | $2.4M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 26,640 | $30 | $905.8K |
| 87483 | The lab analyst performs the technical steps to detect multiple types or subtypes of possible central nervous system pathogens listed in the code. The analyst uses multiplex amplified probe technique… | 1,370 | $410 | $560.6K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 4,740 | $30 | $161.1K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 4,630 | $30 | $157.3K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 4,610 | $30 | $156.6K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 1,040 | $140 | $145.5K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 4,260 | $30 | $144.9K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 1,400 | $90 | $131.7K |
| 86738 | The lab analyst performs an immunoassay to evaluate the patient’s serum for antibodies to mycoplasma. | 7,110 | $10 | $92.4K |
Showing 1–10 of 80
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 80 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
80 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81440 | 5 | 10 | 70 | $3,250 | $634.3K |
| 81443 | 5 | 10 | 70 | $2,400 | $467.4K |
| 81249 | 14 | 20 | 80 | $590 | $319.2K |
| 81238 | 19 | 20 | 110 | $590 | $281.7K |
| 87798 | 9 | 300 | 790 | $30 | $265.1K |
| 87483 | 1 | 10 | 250 | $410 | $211K |
| 81223 | 18 | 30 | 70 | $450 | $197.4K |
| 81490 | 3 | 10 | 170 | $830 | $150.2K |
| 81448 | 5 | 10 | 70 | $570 | $111.7K |
| 87631 | 8 | 90 | 50 | $140 | $90.1K |
Showing 1–10 of 80
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
80 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 12,370 | $40 | $494.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 12,210 | $10 | $158.8K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 11,640 | $10 | $128K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 4,260 | $10 | $51.1K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 2,670 | $10 | $16K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 870 | $10 | $10.4K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 790 | $10 | $6.3K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 2,630 | $1 | $5.3K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 2,600 | $1 | $5.2K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 2,520 | $1 | $5K |
Showing 1–10 of 80
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
80 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81220 | The lab analyst performs the technical lab test to detect the presence of changes in the gene for cystic fibrosis transmembrane conductance regulator, also known as CFTR. The test evaluates the CFTR… | 20 | 20 | 180 | $200 | $923K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 26 | 340 | 400 | $50 | $553.5K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 42 | 240 | 420 | $30 | $296.8K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 120 | 290 | 410 | $20 | $225K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 133 | 300 | 410 | $20 | $223.4K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 38 | 140 | 180 | $60 | $215.9K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 57 | 150 | 320 | $20 | $184K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 50 | 100 | 650 | $50 | $161.3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 28 | 260 | 640 | $20 | $137.2K |
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 13 | 20 | 90 | $120 | $132K |
Showing 1–10 of 80
Other providers in the same ZIP code as Texas Diagnostic Laboratories LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Epic Health Services, Inc. | TX | Home Health Agency | $0 | $67M |
| Assist-med. Inc. | TX | Personal Care Attendant | $0 | $40.5M |
| Minh Dang | TX | Emergency Medicine Physician | $98.6K | $0 |
| Cynthia Kieu | TX | Family Nurse Practitioner | $82.4K | $0 |
| Laurie Reddy | TX | Occupational Therapist | $23.5K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.